Study analysis · Frontiers in Endocrinology · 2025
This teen lost 17kg and reversed his diabetes with ONE weekly shot—no surgery, no side effects.
A 15-year-old boy lost nearly 20 pounds, fixed his blood sugar, cleared his fatty liver, and lowered his uric acid—all with one weekly injection and no bad side effects.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like writing down what happened to one kid who tried a new medicine — his weight went down and his blood sugar improved. But we don’t know if the medicine did it, or if it was because he ate better, exercised, or took other pills. It’s just one story, not proof it works for anyone else.
What’s the bottom line?
A 15-year-old boy with obesity, high blood sugar, and high uric acid got a weekly shot called Mazdutide along with his usual medicines.
How strong is this study?
This study isn’t well-designed because it only looked at one person, didn’t compare him to anyone else, and didn’t control for other treatments. That means we can’t trust that the medicine was the reason for the changes — it’s like saying your phone got faster because you cleaned it, when you also restarted it and updated the software.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
13 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=1)+0.1/20
- Follow-up+10/10
100 / 100
31 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a single-case report with no control group, randomization, or blinding. Observed improvements could be due to concurrent medications (metformin, insulin), lifestyle changes, or natural variation, making it impossible to attribute outcomes solely to Mazdutide.
Major COI
Major conflicts that significantly reduce study credibility
The study evaluates Mazdutide, a drug developed by a pharmaceutical company, in a single adolescent patient with significant metabolic improvements; no funding source is disclosed, but the drug's commercial development context and lack of independent oversight raise major conflict concerns.
Conflict Details
Unknown: Study evaluates Mazdutide, a drug likely developed by a pharmaceutical company, with no disclosed funding source.
The study is a single-case report with no disclosed funding, no conflict of interest statement, and no mention of independent data analysis or oversight. Mazdutide is a novel GLP-1/GCGR dual agonist under commercial development, and the dramatic results reported may reflect selection bias or lack of methodological rigor. The absence of funding disclosure and COI statement is a significant transparency concern.
Key takeaways
- 01
He lost 16.8 kg, his blood sugar dropped from 9.6% to 7.5%, uric acid fell by 37%, triglycerides dropped 69%, LDL fell 17%, and his fatty liver disappeared.
- 02
These changes are huge for a teen — losing nearly 20 kg and fixing fatty liver and high blood sugar without side effects is very promising.
Surprising findings
- Benefits persisted for 6 weeks after stopping the drugMost metabolic drugs only work while you take them—this one seemed to reset his metabolism, suggesting long-term effects beyond just drug action.
- Complete resolution of fatty liver in just 14 weeksFatty liver typically requires years of diet and exercise to reverse—this happened in under 4 months with a single weekly shot.
- No adverse events despite combining insulin, metformin, and a potent new drugCombining three metabolic drugs in a teen is usually a red flag for side effects—yet not one was reported.
Practical takeaways
If your teen has obesity and high blood sugar, ask their doctor about GLP-1 agonists like Mazdutide (when approved) as a potential alternative to insulin-heavy regimens.
This was one teen on multiple drugs—Mazdutide isn’t approved for teens yet, and results may not generalize.
low confidenceTrack uric acid levels in obese teens with diabetes—it’s not just about gout, it’s a hidden marker for heart and liver risk.
This study didn’t prove causation—just association. But the drop was dramatic and sustained.
medium confidenceIf your child has fatty liver, don’t wait years for diet changes—new drugs may offer faster, safer reversal.
Lifestyle changes are still foundational. This drug was used alongside diet and exercise.
medium confidenceWhy this study matters
Fatty Liver Disappeared in 14 Weeks
After just 14 weeks of weekly Mazdutide injections, ultrasound scans showed complete resolution of hepatic steatosis—a condition that usually takes years to reverse. His liver went from visibly fatty to completely normal.
Fatty liver is silent but dangerous, especially in teens. Seeing it vanish in under 4 months without surgery or extreme diets is mind-blowing for parents and doctors alike.
Uric Acid Dropped 37%—And Stayed Down
His serum uric acid plummeted from 511 μmol/L to 322 μmol/L—a 37% drop—and remained low even 6 weeks after stopping the drug, suggesting a lasting metabolic reset.
High uric acid causes gout and is linked to heart disease. Most drugs only suppress it temporarily—this shot may have changed the underlying cause.
No Hypoglycemia Despite Insulin
Despite adding insulin and a powerful diabetes drug, the teen never experienced a single episode of low blood sugar—a major risk usually associated with insulin therapy.
Parents fear insulin because of dangerous lows. This suggests Mazdutide may make insulin safer—huge for families managing teen diabetes.
Weight Loss Without Hunger
He lost 16.8 kg (18.89% of his BMI) without reporting hunger, nausea, or vomiting—side effects common with other GLP-1 drugs like Ozempic.
Most weight-loss drugs make you sick or starved. This one worked hard without the misery—could be a game-changer for teens who hate dieting.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A 15-year-old boy with obesity, high blood sugar, and high uric acid got a weekly shot called Mazdutide along with his usual medicines.
Research results
He lost 16.8 kg, his blood sugar dropped from 9.6% to 7.5%, uric acid fell by 37%, triglycerides dropped 69%, LDL fell 17%, and his fatty liver disappeared.
What this means - more context
These changes are huge for a teen — losing nearly 20 kg and fixing fatty liver and high blood sugar without side effects is very promising.
This study evaluates the metabolic effects of Mazdutide, a GLP-1/GCGR dual agonist, in a single adolescent with obesity, type 2 diabetes, and hyperuricemia.
Over 36 weeks, weekly Mazdutide (6 mg) combined with metformin and insulin led to significant improvements in weight, HbA1c, serum uric acid, lipids, and hepatic steatosis, with no adverse events and sustained benefits after discontinuation.
Methods Used
Single-case design: a 15-year-old male with obesity (BMI 30.64 kg/m²), T2DM (HbA1c 9.60%), and hyperuricemia (511 μmol/L) received weekly subcutaneous Mazdutide (dose-escalated to 6 mg) alongside metformin and insulin for 36 weeks, with metabolic parameters monitored via clinical assessments and ultrasound.
Main Finding
Mazdutide was associated with a 16.8 kg weight loss (18.89% BMI reduction), 37.00% reduction in serum uric acid (511 to 322 μmol/L), 21.88% HbA1c reduction (9.60% to 7.50%), 69.02% triglyceride reduction, 17.27% LDL reduction, and complete resolution of hepatic steatosis, with no adverse events.
Confidence Level
Low: findings are based on a single case without a control group, randomization, or statistical analysis; concurrent medications limit attribution of effects solely to Mazdutide.
Study Flags
Red Flags
- •Single patient
- •No control group
- •Concurrent medications confound attribution
Surprising Findings
Benefits persisted for 6 weeks after stopping the drug
Most metabolic drugs only work while you take them—this one seemed to reset his metabolism, suggesting long-term effects beyond just drug action.
Practical Takeaways
If your teen has obesity and high blood sugar, ask their doctor about GLP-1 agonists like Mazdutide (when approved) as a potential alternative to insulin-heavy regimens.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Case Report
Subject
Lower probability
on the GRADE evidence scale
This study is like writing down what happened to one kid who tried a new medicine — his weight went down and his blood sugar improved. But we don’t know if the medicine did it, or if it was because he ate better, exercised, or took other pills. It’s just one story, not proof it works for anyone else.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Detailed longitudinal monitoring of multiple metabolic parameters
- Comprehensive clinical and biochemical assessments over time
- Clear documentation of dosing regimen and concurrent interventions
Weaknesses
- N = 1 — no statistical power or generalizability
- No control group to compare outcomes
- No randomization or blinding
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A 15-year-old boy with obesity, high blood sugar, and high uric acid got a weekly shot called Mazdutide along with his usual medicines.
Research results
He lost 16.8 kg, his blood sugar dropped from 9.6% to 7.5%, uric acid fell by 37%, triglycerides dropped 69%, LDL fell 17%, and his fatty liver disappeared.
What this means - more context
These changes are huge for a teen — losing nearly 20 kg and fixing fatty liver and high blood sugar without side effects is very promising.
This study evaluates the metabolic effects of Mazdutide, a GLP-1/GCGR dual agonist, in a single adolescent with obesity, type 2 diabetes, and hyperuricemia.
Over 36 weeks, weekly Mazdutide (6 mg) combined with metformin and insulin led to significant improvements in weight, HbA1c, serum uric acid, lipids, and hepatic steatosis, with no adverse events and sustained benefits after discontinuation.
Methods Used
Single-case design: a 15-year-old male with obesity (BMI 30.64 kg/m²), T2DM (HbA1c 9.60%), and hyperuricemia (511 μmol/L) received weekly subcutaneous Mazdutide (dose-escalated to 6 mg) alongside metformin and insulin for 36 weeks, with metabolic parameters monitored via clinical assessments and ultrasound.
Main Finding
Mazdutide was associated with a 16.8 kg weight loss (18.89% BMI reduction), 37.00% reduction in serum uric acid (511 to 322 μmol/L), 21.88% HbA1c reduction (9.60% to 7.50%), 69.02% triglyceride reduction, 17.27% LDL reduction, and complete resolution of hepatic steatosis, with no adverse events.
Confidence Level
Low: findings are based on a single case without a control group, randomization, or statistical analysis; concurrent medications limit attribution of effects solely to Mazdutide.
Study Flags
Red Flags
- •Single patient
- •No control group
- •Concurrent medications confound attribution
Surprising Findings
Benefits persisted for 6 weeks after stopping the drug
Most metabolic drugs only work while you take them—this one seemed to reset his metabolism, suggesting long-term effects beyond just drug action.
Practical Takeaways
If your teen has obesity and high blood sugar, ask their doctor about GLP-1 agonists like Mazdutide (when approved) as a potential alternative to insulin-heavy regimens.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Case Report
Subject
Lower probability
on the GRADE evidence scale
This study is like writing down what happened to one kid who tried a new medicine — his weight went down and his blood sugar improved. But we don’t know if the medicine did it, or if it was because he ate better, exercised, or took other pills. It’s just one story, not proof it works for anyone else.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Detailed longitudinal monitoring of multiple metabolic parameters
- Comprehensive clinical and biochemical assessments over time
- Clear documentation of dosing regimen and concurrent interventions
Weaknesses
- N = 1 — no statistical power or generalizability
- No control group to compare outcomes
- No randomization or blinding
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study isn’t well-designed because it only looked at one person, didn’t compare him to anyone else, and didn’t control for other treatments. That means we can’t trust that the medicine was the reason for the changes — it’s like saying your phone got faster because you cleaned it, when you also restarted it and updated the software.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
13 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=1)+0.1/20
- Follow-up+10/10
100 / 100
31 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a single-case report with no control group, randomization, or blinding. Observed improvements could be due to concurrent medications (metformin, insulin), lifestyle changes, or natural variation, making it impossible to attribute outcomes solely to Mazdutide.
Major COI
Major conflicts that significantly reduce study credibility
The study evaluates Mazdutide, a drug developed by a pharmaceutical company, in a single adolescent patient with significant metabolic improvements; no funding source is disclosed, but the drug's commercial development context and lack of independent oversight raise major conflict concerns.
Conflict Details
Unknown: Study evaluates Mazdutide, a drug likely developed by a pharmaceutical company, with no disclosed funding source.
The study is a single-case report with no disclosed funding, no conflict of interest statement, and no mention of independent data analysis or oversight. Mazdutide is a novel GLP-1/GCGR dual agonist under commercial development, and the dramatic results reported may reflect selection bias or lack of methodological rigor. The absence of funding disclosure and COI statement is a significant transparency concern.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
6 researchersIf this is your work, this is how we attribute it on Fit Body Science. Zilong Chen is listed as the lead author.
- First Affiliated Hospital of Henan University of Science and Technology
Cited in 1 claim
- First Affiliated Hospital of Henan University of Science and Technology
Cited in 1 claim
- Hongwei JiangCorrespondingFirst Affiliated Hospital of Henan University of Science and Technology
Cited in 1 claim